Severely suppressed bone turnover: a potential complication of alendronate therapy.
By C. Odvina, J. Zerwekh, D. Rao, N. Maalouf, F. Gottschalk, C. Pak. Journal of Clinical Endocrinology and Metabolism, 2005
1,451 citations recorded by the source corpus.
Subfields: Oncology, Orthopedics and Sports Medicine
View Paper: https://www.semanticscholar.org/paper/42c1751640f6e37e7058b94adfcbf5b5fd0ac056
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Orthopedics and Sports Medicine
Citations in the corpus
- Bisphosphonates: the first 40 years. (2011, background): “of prolonged high doses of BPs may impair bone turnover to such an extent that bone strength is impaired [82,83].”
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (2008, neutral): “The significance of this is uncertain [123, 124].”
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research (2010, background): “In only a minority of cases have BTMs been suppressed.((13,109,116))”
- Denosumab and bisphosphonates: different mechanisms of action and effects. (2011, background): “In patients receiving long-term bisphosphonate (particularly alendronate) therapy for 5–10 years, there have been reports of atypical subtrochanteric femoral fractures, which have been linked with impaired bone remodeling [174].”
- Bisphosphonates: Mechanism of Action and Role in Clinical Practice (2008, neutral): “126,127 Nonetheless, the optimal duration of bisphosphonate therapy for postmenopausal osteoporosis, and nearly all other conditions for which bisphosphonates are used, remains unclear.”
- Osteoclasts: what do they do and how do they do it? (2007, positive): “The same occurs in some patients treated for many years with resorption-inhibiting bisphosphonates, which dampen remodeling.(86) The retarded bone remodeling characterizing prolonged GC therapy raises the counterintuitive argument that prevention of skeletal complications may actually require some r”